HUTCHMED (China) Limited
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- HUTCHMED (China) Limited is an innovative commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted therapeutics and immunotherapies primarily for cancer and immunological diseases. The company’s main products include oncology and immunology drugs such as FRUZAQLA® (fruquintinib), a targeted therapy for colorectal cancer marketed in over 30 countries through its partner Takeda, and savolitinib (ORPATHYS®), a selective oral MET inhibitor for non-small cell lung cancer, developed in collaboration with AstraZeneca. HUTCHMED’s product portfolio also encompasses antibody-targeted therapy conjugates (ATTCs), combining antibodies with targeted therapeutics, with new clinical candidates expected to enter trials in late 2025. The company operates through its Oncology/Immunology segment, focused on drug discovery and commercialization, alongside other ventures including the manufacture, sale, and distribution of prescription drugs and healthcare products primarily in China. HUTCHMED was founded in 2000 and is headquartered in Hong Kong. It conducts global clinical development and commercialization activities, with significant operations in China, the US, Europe, and Japan. The company maintains partnerships for commercial and clinical development, including licensing arrangements with multinational pharmaceutical companies such as Takeda and AstraZeneca. In recent strategic developments, HUTCHMED completed a $608 million divestment of a 45% equity interest in its non-core joint venture Shanghai Hutchison Pharmaceuticals (SHPL) to focus on its core business of innovative drug development, specifically its antibody-targeted therapy conjugate platform. This divestment occurred in early 2025 and is intended to fund advancement in its core oncology pipeline. HUTCHMED also reported significant sales growth in oncology products in 2024, with FRUZAQLA® achieving over $290 million in ex-China sales, and expanded its commercial reach globally. The company launched new clinical studies and expanded indications for its key therapies, including positive phase II results for savolitinib in combination with osimertinib for lung cancer. HUTCHMED continues to enhance its pipeline with new ATTC platform candidates and is preparing for additional product launches, including sovleplenib for idiopathic thrombocytopenic purpura in China. Overall, HUTCHMED leverages in-house research and a broad clinical pipeline in oncology and immunology with robust commercialization efforts and strategic global partnerships to drive growth and innovation in biopharmaceuticals. The company has around 1,800 employees and remains committed to expanding its global footprint while focusing on advanced therapeutic modalities and targeted therapies. This description integrates HUTCHMED’s main products, geographic reach, founding, and headquarters details, with the latest changes including its 2025 divestment of SHPL, pipeline advancements, drug launches, and strong sales performance in oncology therapeutics.
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms
Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) PT at $16.88
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
Paycom Receives HCM Technology Signal Award for Workforce Change
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
HUTCHMED H2 Earnings Call Highlights
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript
Workday Faces Pressure as FY27 Guidance Highlights Slower Growth
HUTCHMED (China) Limited Sponsored ADR $HCM Shares Sold by M&G PLC
HCM IV Acquisition Corp Announces Pricing of $250 Million Initial Public Offering